RPL11 and cancer: As a decreased expression of RPL11 leads to reduced sensitivity to topoisomerase inhibitors, the development of drugs that increase RPL11 expression could contribute to increasing the efficacy of topoisomerase inhibitors and overcoming resistance in cancers.